Immunity Pharma
Clinical-stage biopharmaceutical company developing peptide-based therapeutics that activate intracellular Akt signaling to treat neurodegenerative diseases, initially focusing on amyotrophic lateral sclerosis (ALS). Lead candidate (IPL344) has completed an open-label phase 1/2a program with safety, tolerability, biomarker and preliminary efficacy data reported and holds orphan drug designation from FDA and EMA.
Industries
Nr. of Employees
small (1-50)
Immunity Pharma
Patents
Products
IPL344
A biologically active peptide developed to activate intracellular Akt signaling independent of cell-surface receptors; evaluated in preclinical ALS models and in an open-label phase 1/2a clinical program in ALS patients.
IPL peptides
Proprietary peptide therapeutics developed by Immunity Pharma that modulate the Akt signaling pathway and restore Akt activity to normal levels independently of cell membrane receptors to support pro-survival processes in neurodegenerative diseases.
IPL344
A biologically active peptide developed to activate intracellular Akt signaling independent of cell-surface receptors; evaluated in preclinical ALS models and in an open-label phase 1/2a clinical program in ALS patients.
IPL peptides
Proprietary peptide therapeutics developed by Immunity Pharma that modulate the Akt signaling pathway and restore Akt activity to normal levels independently of cell membrane receptors to support pro-survival processes in neurodegenerative diseases.
Expertise Areas
- Clinical trial management (early-phase, open-label and dose-escalation)
- Peptide therapeutics development
- Neurodegenerative disease therapeutics (ALS focus)
- Preclinical efficacy testing in ALS animal models
Key Technologies
- Akt pathway modulation
- Peptide-based therapeutics
- SOD1 ALS mouse model
- Intravenous bolus home infusion protocol
News & Updates
Peer-reviewed article reporting first-in-human open-label results for IPL344 showing safety, tolerability, biomarker and exploratory efficacy findings.
Poster reporting reductions in plasma NfL concentrations following IPL344 treatment (Phase 1/2a trial).
Regulatory authorities granted orphan drug designation to IPL344 for ALS, providing regulatory exclusivity benefits.
Open-label phase 1/2a program reported safety, tolerability, mean reductions in ALSFRS-R slope compared with historical controls, NfL reductions and signals in weight, respiratory function and survival.
Peer-reviewed article reporting first-in-human open-label results for IPL344 showing safety, tolerability, biomarker and exploratory efficacy findings.
Poster reporting reductions in plasma NfL concentrations following IPL344 treatment (Phase 1/2a trial).
Regulatory authorities granted orphan drug designation to IPL344 for ALS, providing regulatory exclusivity benefits.
Open-label phase 1/2a program reported safety, tolerability, mean reductions in ALSFRS-R slope compared with historical controls, NfL reductions and signals in weight, respiratory function and survival.